Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if NHS England will develop a clinical commissioning policy on the use of extended half-life blood clotting factor products in people with haemophilia.

The Department plans to tender for extended half-life Clotting Factor VIII and Factor IX for use in the National Health Service once the products are granted European Union licences and are commercially available.

NHS England has made no decision at this time to whether it will develop a clinical commissioning policy for extended half-life productsbut, through the Clinical Reference Group and discussion with the Department’s Commercial Medicines Unit, will continue to review commissioning of these extended half-life products in the future.